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Introduction: Coagulation abnormalities are frequent in sepsis. Conventional coagulation assays, however, have
several limitations. A surge of interest exists in the use of point-of-care tests to diagnose hypo- and hypercoagulability
in sepsis.
We performed a systematic review of available literature to establish the value of rotational thromboelastography (TEG)
and thromboelastometry (ROTEM) compared with standard coagulation tests to detect hyper- or hypocoagulability in
sepsis patients. Furthermore, we assessed the value of TEG/ROTEM to identify sepsis patients likely to benefit from
therapies that interfere with the coagulation system.
Methods: MEDLINE, EMBASE, and the Cochrane Library were searched from 1 January 1980 to 31 December
2012. The search was limited to adults, and language was limited to English. Reference lists of retrieved articles
were hand-searched for additional studies. Ongoing trials were searched on www.controlled-trials.com and
www.clinicaltrials.gov. Studies addressing TEG/ROTEM measurements in adult patients with sepsis admitted to
the ICU were considered eligible.
Results: Of 680 screened articles, 18 studies were included, of which two were randomized controlled trials, and
16 were observational cohort studies. In patients with sepsis, results show both hyper- and hypocoagulability, as
well as TEG/ROTEM values that fell within reference values. Both hyper- and hypocoagulability were to some extent
associated with diffuse intravascular coagulation. Compared with conventional coagulation tests, TEG/ROTEM can
detect impaired fibrinolysis, which can possibly help to discriminate between sepsis and systemic inflammatory
response syndrome (SIRS). A hypocoagulable profile is associated with increased mortality. The value of TEG/ROTEM
to identify patients with sepsis who could possibly benefit from therapies interfering with the coagulation system could
not be assessed, because studies addressing this topic were limited.
Conclusion: TEG/ROTEM could be a promising tool in diagnosing alterations in coagulation in sepsis. Further research
on the value of TEG/ROTEM in these patients is warranted. Given that coagulopathy is a dynamic process, sequential
measurements are needed to understand the coagulation patterns in sepsis, as can be detected by TEG/ROTEM.Introduction
Coagulopathy is highly prevalent in sepsis patients and is
associated with increased mortality [1]. Coagulopathy re-
sults from an imbalance between activation of coagulation
and impaired inhibition of coagulation and fibrinolysis.
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reproduction in any medium, provided the orsystem leads to a variable clinical picture, ranging from an
increased bleeding tendency due to consumption of co-
agulation factors and platelets, to hypercoagulopathy with
disseminated intravascular coagulation (DIC) and (micro-)
vascular thrombosis.
Assessment of coagulation status in these patients is com-
plex. Global coagulation tests activating partial thromboplas-
tin time (APTT) and prothrombin time (PT) are used
clinically. However, their ability to reflect in vivo hypocoa-
gulability accurately is questioned [2]. Also, APTT and PT
reflect only a part of the coagulation system and do notLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and anticoagulation. Activation of coagulation can be
assessed by thrombin generation, but this test is not
widely available. Impaired function of the anticoagu-
lant system can be diagnosed by measuring plasma
levels of naturally occurring anticoagulant factors anti-
thrombin (AT), protein C, protein S, and tissue factor
pathway inhibitor (TFPI). However, these are not read-
ily available for clinical use. The same applies to markers
of the activity of the fibrinolytic system [2]. Although acti-
vation of the fibrinolytic system can be detected by in-
creased levels of D-dimers and other fibrin-degradation
products, specificity is limited [2].
Rotational thromboelastography (TEG) and thromboelas-
tometry (ROTEM) are point-of-care tests, which evaluate
whole-clot formation and dissolution. The thromboelasto-
gram arises through movement of the cup (TEG) or the
pin (ROTEM). As fibrin forms between the cup and the
pin, this movement is influenced and converted to a trace
reflecting different phases of the clotting process. Major pa-
rameters are reaction time (R) or clotting time (CT), which
is the period from the initiation of the test until the begin-
ning of clot formation (Figure 1). K-time or clot formation
time (CFT) is the period from the start of the clot forma-
tion until the curve reaches an amplitude of 20 mm. Kinet-
ics of fibrin formation and cross-linking are expressed by
the α-angle, which is the angle between the baseline and
the tangent to the TEG/ROTEM curve amplitude. Clot
strength is represented by the maximal amplitude of the
trace. The degree of fibrinolysis is reflected by the differ-
ence between the maximal amplitude and the amplitude
measured after 30 and/or 60 minutes (Figure 1). To de-
scribe these viscoelastic changes, both systems have their
own terminology (Table 1).
The technique was developed in the 1940s, but clinical
application has been limited. However, technical devel-
opments have led to standardization and improvedFigure 1 ROTEM trace with major parameters. Reference: www.rotem.dreproducibility of the method [3,4]. TEG/ROTEM may
facilitate diagnosis of clotting abnormalities in sepsis, in-
cluding hypercoagulable states such as DIC. Other poten-
tial advantages could be a more tailor-made administration
of therapies that interfere with the coagulation system
[5-8]. These tests also may improve prognostication of
sepsis [9,10].
The main research questions for this systemic review
were as follows. Can TEG/ROTEM detect sepsis-induced
coagulopathy? Is TEG/ROTEM of additional value com-
pared with standard coagulation tests to detect hyper- or
hypocoagulability in sepsis patients? Can TEG/ROTEM
help to identify sepsis patients likely to benefit from ther-
apies that interfere with the coagulation system (for ex-
ample, activated protein C, antithrombin, heparin)? We
defined our population as critically ill adults with sepsis
and TEG/ROTEM as the intervention. Standard coagula-
tion tests, including APTT, PT, INR, and ISTH DIC score,
functioned as comparisons. Outcomes of interest were the
detection of a hyper- or hypocoagulable state in these pa-
tients and the identification of patients likely to benefit
from therapies affecting the coagulation system.
Materials and methods
Data sources
An electronic search was conducted in MEDLINE,
EMBASE, and the Cochrane Library. In addition, we
searched for ongoing trials on www.controlled-trials.
com and www.clinicaltrials.gov. We hand-searched the
reference lists of retrieved articles, reviews, and editorials
for additional studies. Language was limited to articles
written in English and published from 1 January 1980 to
31 December 2012. We did not register our protocol.
Study selection
Two authors (MCM and NPJ) performed the literature
search and selected the relevant articles for inclusion.e.
Table 1 Parameters displayed on TEG and ROTEM
TEG ROTEM
Time to initial fibrin formation
(to 2-mm amplitude)
R CT




Clot strength, represents maximum
dynamics of fibrin and platelet
bonding
MA MCF
Clot breakdown, fibrinolysis at
fixed time
CL30, CL60 LI30, LI45, LI60
Reference: www.rotem.de and www.haemoscope.com.
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fined eligibility criteria were used. Studies were included
if TEG/ROTEM measurements were performed in adult
patients with sepsis admitted to the ICU. Randomized
controlled trials, prospective and retrospective cohorts,
and case series were all eligible for inclusion. Reviews,
correspondences, case reports, expert opinions, and edito-
rials were excluded. We also excluded all studies con-
ducted outside the ICU or that involved subjects younger
than 18 years.
Data-collection process
Two of the authors (MCM and NPJ) independently ex-
tracted the data by using a predefined extraction sheet.
Discrepancies were resolved in a consensus meeting. If
agreement could not be reached, a third author was con-
sulted (MBV) to resolve disagreement. The extracted
data were general methodologic characteristics, setting,
characteristics of the study population, used test (ROTEM
or TEG), timing of thromboelastography, possible com-
parison of thromboelastography results with a reference
test, administration of therapies interfering with the
coagulation system, and main outcomes. Furthermore,
possible limitations of each study were listed. No as-
sumptions or simplifications were made.
Assessment of methodologic quality
We used the QUADAS-2 checklist to assess the quality
of diagnostic studies [11,12]. Studies were assessed for
the risk of bias in patient selection, conduct and inter-
pretation of TEG/ROTEM, use and interpretation of a
reference standard, and patient flow. For all research
questions, methodologic aspects, including the use of a
comparison of TEG/ROTEM measurement, the individ-
ual studies were assessed. Furthermore, studies were
judged with respect to patient population and selection
(use of definition of sepsis). Details on how TEG/ROTEM
and reference tests were conducted and interpreted (for
example, timing of the tests, blinded interpretation) were
assessed. Subsequently, quality of evidence was judged
and described in accordance with the GRADE approach(high, moderate, low, and very low). Rating of quality of
evidence was based on trial design (for example, random-
ized clinical trial or not), risk of bias and imprecision (for
example, patient selection and patient flow, method of
conduct and interpretation of TEG/ROTEM, and refer-
ence test results). We verified whether results of the re-
trieved trials and abstracts had been published.
Definitions
Hypocoagulability can be defined as prolonged CT/R
and CFT/K times and/or decreased MCF/MA and alpha
angle [4]. Conversely, a hypercoagulable state can be de-
tected by shortened reaction times (CT/R and/or CFT/K)
and enhanced clot formation, expressed as increased alpha
and/or high maximal amplitude (MCF/MA). However, no
universal definitions of hypo- and hypercoagulability
assessed by TEG/ROTEM exist.
Results
Study selection
Of 680 screened articles, we included 18 studies (Table 2).
An overview of the search is presented in Figure 2.
Twenty-six studies were excluded because of inappropri-
ate patient population (N = 21 [13-33]), no report of TEG/
ROTEM data (N = 6 [31,32,34-37]), and one conference
poster [38].
Study characteristics
We included two randomized controlled trials [39,40]
and 16 observational studies [9,10,41-54]. Of the obser-
vational studies, 14 were prospective and one abstract
[45] and one article [42] did not state whether the study
was prospective or retrospective. Of the included stud-
ies, 11 [9,10,41,43,44,48-51,53,54] used the sepsis and
SIRS criteria defined by the Society of Critical Care
Medicine Consensus Conference [55]. Seven studies
used TEG [10,39,40,42,49,51,53], and 11 used ROTEM
[9,41,43-48,50,52,54].
Risk of bias
The risk of bias within studies is summarized in Table 3.
Quality assessment revealed that risk of bias of patient
selection was low. However, included studies were het-
erogeneous regarding conduction and interpretation of
TEG/ROTEM, and no studies reported whether results
of TEG/ROTEM were interpreted with or without
knowledge of the used reference test, which leaves the
possibility for interpretation bias. However, applicability
concerns of the chosen reference tests are low.
In addition to individual sources of bias related to de-
sign and methods, we identified the lack of information
about the conduct and interpretation of the TEG/
ROTEM test and results as the most important source
of bias across all studies (Table 3). We verified whether
Table 2 Studies assessing TEG/ROTEM in sepsis




Comparison Main ROTEM/TEG findings
Gonano [40] Subanalysis of randomized
controlled trial
Severe sepsis (n = 33) TEG At diagnosis and daily
thereafter.
PT, APTT, AT All patients were hypercoagulable (shortened
R and CT, increased α and MA). Antithrombin





Severe sepsis and septic
shock (n = 16)
TEG Daily for 2 weeks and
day 17, 20, 23, 28
PAI-1 In patients without tight glycemic control (TGC),
fibrinolysis was decreased (increased lysis index
and increased PAI-1), compared with sepsis
patients not treated with TGC.
Collins [43] Prospective observational Sepsis (n = 38), healthy
controls (n = 32)
ROTEM Not stated PT, APTT fibrinogen,
factor levels
In sepsis, there was delayed activation of
hemostasis, once activated clot formation
was exaggerated (increased MCF, α angle, area
under clot firmness curve)
Chiari (abstract)
[47]
Prospective observational Severe sepsis (n = 15) ROTEM Before and first day of
treatment with activated
protein C
APTT, PT Only CT significantly increased with activated
protein C treatment




All parameters within reference values. Patients
with SOFA >10 had increased coagulation
(reduced MCF and alpha and increased CFT).
Schmittinger
(abstract) [46]
Prospective observational Severe sepsis (n = 49),
postoperative
SIRS (n = 27)
ROTEM Day 1, 4, 7 after
admission
None All parameters within reference values. Mortality
58.3% in patients with signs of hypocoagulation
vs. 9.1% in those with signs of hypercoagulability.
Sivula [41] Prospective observational Severe sepsis (n = 28),
healthy controls (n = 8)
ROTEM Day 1 APTT, AT, D-dimer,
fibrinogen
Only sepsis patients with DIC were hypocoagulable
compared to healthy controls. CFT, alpha
and MCF discriminated well between DIC and
non- DIC. Decreased fibrinolysis in all sepsis
patients versus controls.
Adamzik [50] Prospective observational Sepsis (n = 56), postoperative
controls (n = 52)




Increased lysis index in sepsis compared to
postoperative controls (97 ± 0.3% vs. 92 ± 0.5%,
p < 0.001). CFT, alpha and MCF did not differ
between groups. Lysis index had best accuracy for
diagnosis sepsis.
Altmann [48] Prospective observational Septic shock (n = 16), severe
sepsis (n = 7), SIRS (n = 10)
ROTEM 0, 12, 24, 48 h after
inclusion
None All parameters within reference values.
Durila [49] Prospective observational Severe sepsis (n = 44) TEG Not stated INR, APTT, fibrinogen,
AT
All parameters within reference values.
Adamzik [9] Prospective observational Sepsis (n = 98) ROTEM Within 24 hours of
diagnosis
INR 39% of sepsis patients had normal CFT, MCF, and α
angle, values in 61% with pathologic variable
showed broad distribution Hypocoagulable profile




Prospective observational Severe sepsis (n = 31),
postoperative (n = 31)
TEG Within 12 hours of
diagnosis
None Sepsis patients had lower α angle, other TEG













Table 2 Studies assessing TEG/ROTEM in sepsis (Continued)
Brenner [54] Prospective observational Septic shock (n = 30), major
surgery (n = 30), healthy
volunteers (n = 30)
ROTEM Sepsis: at diagnosis,
24 h, 4, 7, 14, 28 days
Prothrombin index,
factor levels, IL-6, TNF-α
In sepsis patients, majority of ROTEM analysis within
reference values; however, sepsis patients with DIC
showed more hypocoagulable traces compared with
those without DIC were more hypercoagulable
Compared with surgical and healthy controls
fibrinolysis was impaired in sepsis patients.
Durila [53] Prospective observational Postsurgical esophagectomy
(n = 38), of these, nine
developed sepsis.
TEG Morning of surgery and
daily day 1-6 post
operative
APTT, INR, CRP, lactate,
IL-6, procalcitonin, AT,
D-dimer
On postoperative day 6, sepsis patients had higher
lysis index compared with SIRS patients. Overall TEG
not helpful in discriminating sepsis from SIRS
Massion [52] Prospective cohort Septic shock (n = 39) ROTEM Admission to day 7 APTT, PT, Thrombin
generation, factor levels,
AT, protein C
Fibrinolysis was decreased (increased lysis indexes),
associated with hypocoagulation in conventional
coagulation tests (decreased protein C and AT). Other
parameters within reference values (CT, MCF and
alpha). Nonsurvivors were more hypocoagulable,
but ROTEM values were not independently associated
with mortality
Ostrowski [10] Prospective observational Severe sepsis (N = 13) and
septic shock (N = 37)
TEG Day 1-4 ISTH DIC score, INR,
APTT, D-dimer,
fibrinogen, CRP
According to cloth strength (MA), 48% of sepsis
patients was normocoagulable, 22%
hypocoagulable and 30% hypercoagulable.
50% of patients with hypocoagulable profile had
overt DIC, versus none of those with a
hypercoagulable profile. Hypocoagulable profile
predicts 28-day mortality if corrected for SOFA,
but not if corrected for SAPS II score.
Viljoen [42] Not stated Sepsis (n = 15), trauma (n = 14),
surgery (n = 21), healthy
control (n = 23)
TEG Daily Plasma elastase-α
sub 1 PI
Sepsis patients were hypocoagulable compared with
surgery patients and controls. Sepsis patients had
higher elastase-α sub1 proteinase inhibitor levels




Not stated Sepsis (n = 21), no sepsis
(n = 23)
ROTEM Not stated Thrombin time,
D-dimer, AT














Figure 2 PRISMA flow diagram.
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been published at December 31, 2012. Construction of a
funnel plot was not feasible because of characteristics of
retrieved studies.
Synthesis of results
Studies varied widely in the way they were conducted.
Main differences were timing of TEG/ROTEM measure-
ments, number of measurements, use of preset reference
values or control group to assess derangements in TEG/
ROTEM measurements in sepsis, and variable use of dif-
ferent comparison tests. Because of this clinically rele-
vant heterogeneity, we carried out a narrative synthesis
of the results of the included studies.
Ability of TEG/ROTEM to detect sepsis-induced
coagulopathy
In five studies, all TEG/ROTEM measurements in sepsis
were within reference values [44,46,48,49,54]. These studies
included a total of 176 sepsis and severe sepsis patients. In
seven studies, TEG/ROTEM revealed pathologic changes
ranging from distinct hypercoagulability [40] to predomin-
antly hypocoagulable profiles [42,51]. Four prospective ob-
servational studies, together including 214 patients, reported
heterogeneous results with patients showing hyper- and
hypocoagulability [9,10,41,43]. Impaired fibrinolysis in sepsis
patients was demonstrated in five different observationalstudies, with a total of 162 patients [41,50,52-54]. Two of
these studies reported increased lysis indices as the only ab-
normal ROTEM parameter in 30 and 39 patients with septic
shock [52,54]. In a small cohort of 16 patients with severe
sepsis; patients were randomized to tight glycemic control
or conventional glucose levels; strict regulation of glucose
levels resulted in enhancement of fibrinolysis, as measured
by lysis index with ROTEM [39].
Overall, if sepsis-induced coagulopathy was detected,
the proportion of sepsis patients with sepsis-induced co-
agulopathy that was detected by TEG/ROTEM ranged
from 43% to 100% [9,10,40,41].
Altogether, in the majority of studies, TEG/ROTEM
was able to detect sepsis-induced coagulopathy. How-
ever, changes in parameters were heterogeneous, and
study designs varied widely, with a lack of clarity in in-
terpretation of test results. Based on this, the quality of
evidence supporting the use of TEG/ROTEM to detect
sepsis-induced coagulopathy is considered low.
Additional value of TEG/ROTEM in sepsis compared with
standard coagulation tests
Studies designed to compare conventional coagulation
tests directly with TEG/ROTEM for the detection of
sepsis-induced coagulopathy were not retrieved.
However, two studies assessed the value of thromboe-
lastography in the detection of DIC. A prospective pilot
Table 3 Summary of risk of bias and applicability concerns for included studies








Patient flow Patient selection Reference
standard
Gonano et al. [40] - ? - ? - -
Raineri et al. [39] ? ? - - - -
Collins et al. [43] ? ? - ? - -
Chiari et al. [47] - ? - ? - -
Daudel et al. [44] - - - ? - -
Schmittinger et al. [46] - - NA - - NA
Sivula et al. [41] - ? ? ? - -
Adamzik et al. [50] - ? ? - - -
Altmann et al. [48] - ? NA NA - NA
Durila et al. [49] - + - - - -
Adamzik et al. [9] - - - + - -
Cortegiani et al. [51] ? ? NA - - NA
Brenner et al. [54] - - - - - -
Durila et al. [53] - ? ? + - -
Massion et al. [52] - ? - - - -
Ostrowski et al. [10] - - - + - -
Viljoen et al. [42] + ? ? ? + +
Umgelter et al. [45] + + NA ? + NA
-, low risk; +, high risk; ?, unclear risk; NA, not applicable.
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angle discriminated moderately between overt DIC and
no DIC. ROC values were 0.815 (CI, 0.624 to 0.935) for
CFT, 0.891 (CI, 0.715 to 0.975) for MCF, and 0.828 (CI,
0.639 to 0.943) for α angle. Combination of CFT, MCF,
and α resulted in a sensitivity of 100% and a specificity
of 75%, with a positive likelihood ratio of 4.0 and nega-
tive likelihood ratio of 0.0 for the diagnosis of DIC [41].
A recent study showed that ROTEM values were
within reference values. However, patients with overt
DIC had prolonged CFT and reduced MCF compared
with those without DIC. ROC curves for MCF in EXTEM
(0.806; sensitivity, 79%; specificity, 75%) and MCF in
INTEM (0.853; sensitivity, 86%; and specificity, 81%)
achieved fairly good results [54].
Interestingly, TEG/ROTEM failed to detect coagulopa-
thy in two observational studies, whereas conventional
coagulation assays were outside normal ranges [44,49].
In 44 sepsis patients, mean INR, D-dimer, and fibrino-
gen levels were increased, whereas mean TEG values
were not [49]. A study of 30 sepsis patients revealed
similar results, with decreased levels of individual factor
levels and increased APTT tests, whereas ROTEM vari-
ables remained within reference values [44].
Some studies addressed the question whether TEG/
ROTEM was superior in discriminating sepsis fromnonsepsis patients compared with conventional bio-
markers. Indeed, two observational studies demonstrated
that the lysis index derived from thromboelastometry
could be helpful to discriminate between sepsis and
postoperative inflammatory response [50,54]. Decreased
fibrinolytic activity, as reflected by the lysis index, was
found to discriminate sepsis from postoperative SIRS pa-
tients (ROC-AUC, 0.811; sensitivity, 93%; specificity,
50%), which was comparable to CRP and procalcitonin
[54]. In a larger cohort of 56 sepsis patients and 52 post-
operative controls, lysis index had even better diagnostic
value than did procalcitonin (ROC-AUC, 0.901; sensitiv-
ity, 84%; and specificity, 94%) [50]. In contrast, in cirrhosis
patients and postesophagectomy patients, thromboelasto-
metry variables failed to discriminate between sepsis and
nonsepsis patients [45,53].
Ability of TEG/ROTEM to identify patients likely to benefit
from anticoagulant treatment in sepsis
We hypothesized that TEG/ROTEM might help to iden-
tify patients likely to respond to therapies that target coag-
ulopathy. However, we did not find any study addressing
this question. The only data on TEG/ROTEM and therapy
interfering with coagulation consist of a few small patient
series evaluating TEG/ROTEM measurements during
anticoagulant treatment. In an observational study of
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ments did not change during treatment [47]. Gonano
[40] showed distinct hypercoagulability in 33 patients
with severe sepsis, of whom 17 were treated with anti-
thrombin. In these patients, hypercoagulability was not
reversed by the treatment.
Use of TEG/ROTEM in prognostication of outcome
Although initially not looked for, we extracted a limited
number of studies that addressed the value of TEG/
ROTEM in predicting outcome in sepsis and decided
post hoc to add these data to the review. In a cohort of
98 sepsis patients, by using multivariate analysis, a hypo-
coagulable profile on admission was shown to be an inde-
pendent risk factor for 30-day mortality (OR, 4.1; 95% CI,
1.4 to 11.9) [9]. However, not all studies have unequivo-
cally showed the prognostic value of hypocoagulability
with mortality after correcting for disease severity [10,52].
In 50 patients with severe sepsis, hypocoagulable TEG
MA at admission was an independent predictor for
28-day mortality in a multivariate model including
SOFA score (hazard ratio, 4.29 (1.35 to 13.65); P =
0.014), but not in a model using SAPS II score (hazard
ratio, 2.32 (0.66 to 8.15); P = 0.188) [10]. Of note, in a
multivariate model a hypocoagulable profile due to a
persistent deficit in thrombin generation was a strong
predictor of hospital mortality (P = 0.024), as was
APTT (P = 0.007) [52]. The presence of hypercoagula-
bility did not predict outcome.
Quality of evidence of studies addressing the value of
TEG/ROTEM to predict mortality is considered of mod-
erate quality. Of note, in these studies, most patients had
thromboelastography values outside reference ranges.
Discussion
This systematic review on studies performing TEG/
ROTEM measurements in sepsis patients shows that
studies were heterogeneous in design, use of control
groups, timing of TEG/ROTEM measurements, and
chosen end points. Internal validity of most studies is
limited. Although most studies included sepsis patients
according to the ACCM/SCCP definition, external valid-
ity is limited because of relatively small patient groups in
most studies. Furthermore, standardization of used tests
is limited, and most studies had methodologic flaws,
which may have resulted in bias. Thereby, the overall
quality of evidence on the value of TEG/ROTEM in
adults with sepsis is considered low.
Results of TEG/ROTEM measurements in sepsis vary
widely across studies and show both hypo- and hyperco-
agulability [10,40-43,46,51]. This is consistent with the
pathophysiology of “consumption coagulopathy” during
DIC, in which microvascular thrombi are formed at the
expense of a bleeding tendency because of low levels ofplatelets and coagulation factors [56]. Of note, hetero-
geneity of results can also be caused by differences in
disease severity, as changes were more obvious in severe
sepsis patients [40,41,46,51] than in sepsis patients. In
addition, variation in the way studies were conducted
has probably contributed to differences in outcome.
Interestingly, the degree of hypocoagulation was found
to be associated with severity of organ failure [44]. In a
study comparing different patient populations, hypocoa-
gulation measured with TEG was most apparent in sep-
sis patients and associated with a proinflammatory
response and organ failure [42]. Timing of measure-
ments may be relevant to these observations, as hypo-
coagulation was found to be more obvious in the acute
phase of sepsis and returned to normal values toward
discharge from the ICU [44,51].
Included studies varied widely with regard to the de-
tection of hypercoagulability, ranging from 30% [10] to
100% [40], which may have resulted from variation in
timing as well as in the definition of hypercoagulability.
Of note, TEG/ROTEM clearly demonstrated hypercoag-
ulability in models of endotoxemia [57], with a strong
correlation with plasma levels of prothrombin fragments
F1 + 2 [58,59].
In addition to hypo- and hypercoagulability, TEG/ROTEM
can detect impairment in fibrinolysis, expressed as increased
lysis indices. Hypofibrinolysis has been demonstrated in sev-
eral studies in sepsis patients [41,50,52-54], but the clinical
relevance of this finding must be determined. Of note, in-
creased lysis indices were shown to be helpful in discriminat-
ing sepsis and SIRS patients [50,53,54].
TEG/ROTEM has been shown to be promising in
diagnosing DIC, and in particular, the combination of
various parameters (reaction times, maximum ampli-
tude, and α angle) improves diagnostic value [41,54]. A
score to detect DIC with the use of thromboelastometry
has been developed, including prolonged reaction and K
times and decreased α angle and maximum amplitude.
This score was validated in patients with an underlying
disease known to be associated with DIC and with an
ISTH DIC [60] score of more than 5. However, to date,
this score has not been validated in critically ill patients
with sepsis, and included studies in this review consisted
of relatively small patient groups. Therefore to date, qual-
ity of evidence supporting the use of TEG/ROTEM to
diagnose DIC is low, and further research is necessary.
Several factors in the way TEG/ROTEM measure-
ments were conducted may have affected the results of
included studies. First, coagulopathy in sepsis is a dy-
namic process, evolving from subtle activation of coagu-
lation to overt DIC. Therefore, timing may greatly
influence TEG/ROTEM results. Performing sequential
measurements will probably provide better insight into
the development of coagulation derangements. Timing
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widely.
Second, no uniform definitions exist of hypo- and hy-
percoagulability. Reference values for patients with sepsis
are not widely assessed, and only one study determined
cut-off values for a cohort of sepsis patients [9]. Some
studies classified patients as hypo- or hypercoagulable
when measurements were outside preset reference ranges
[10,40,44,46]; others compared patients with healthy indi-
viduals [41,43,50,52,54]; and some compared mean or
median values among or within different patient groups
[9,39,42,45-51,53,54]. To compare patient categories and
possibly investigate therapeutic interventions in the
coagulation system, validated universal reference values
and definitions are essential. For ROTEM, a multicenter
investigation has been undertaken to assess reference
values [4]. A study to verify reference intervals of TEG re-
agents was recently completed (NCT01357928), and we
hope that results will contribute to further standardization
of TEG.
Third, the included studies differed in the types of re-
agents used, which may have considerable effects on the
results of the studies. Most studies using ROTEM used
tissue factor, after recalcification of the citrated sample, to
enhance coagulation [41,43,44,48,52,54], although some
also performed a nonactivated test (NATEM). Of the
studies using TEG, only one study reported the use of
kaolin activation [49]; the others only recalcified samples
before testing. Of note, correlation between non-kaolin-
activated and kaolin-activated thromboelastography has
shown to be poor [61]. Furthermore, in some studies, a
potential heparin effect was blocked by the addition of he-
parinase [9,40,44,50,52,54], whereas others lacked infor-
mation on the use of heparinase [10,42].
In the current review, we included studies using
ROTEM and studies using TEG. None of the included
studies studied both devices. Some studies that com-
pared both devices in other patient populations showed
differences in test results between ROTEM and TEG
[62,63], although not all [64]. Therefore, comparisons of
results of studies using different devices should be made
cautiously.
A hypocoagulable profile detected by TEG/ROTEM
seems to be associated with increased mortality among
sepsis patients [9,10,46]. One could argue that a hypo-
coagulable profile merely reflects severity of disease.
However, in the study of Adamzik [9], hypocoagulable
TEG/ROTEM remained an independent predictor of
mortality after correction for severity of disease. These
findings are in line with results in a larger cohort of gen-
eral intensive care patients, in which a hypocoagulable
profile at admission was associated with an increased
mortality [26]. This relation questions the role of coagu-
lation in inflammatory processes. We speculate thatenhanced coagulation during infection is functional,
thereby preventing dissemination of bacteria. Thereby,
hypocoagulability may facilitate enhanced spread of in-
fection and subsequently mortality [65]. The finding that
hypocoagulability is associated with organ failure and is
an independent risk factor for mortality underlines the
need for further research. Currently, two observational
prospective trials in sepsis patients are being conducted
(NCT00994877 and NCT00299949) on the value of
TEG/ROTEM to diagnose DIC and to predict organ fail-
ure in sepsis. Results of these studies may help to deter-
mine whether TEG/ROTEM can be used to select specific
patient populations who are likely to benefit from therap-
ies aimed at intervention in the coagulation cascade dur-
ing sepsis.
Our review has limitations, which include the lack of a
uniform definition of hypo- and hypercoagulability assessed
by ROTEM or TEG, different reference values, differences
in control groups, and the heterogeneous study quality. An-
other limitation is related to our search, in which we may
have missed studies published in languages other than
English, as well as unpublished data. In addition, we
might have missed studies because of the applied date
restriction and limitation of our search to three databases.
Conclusion
A considerable proportion of sepsis patients have an
altered coagulation status. An abnormal TEG/ROTEM, in
particular hypocoagulability, is prognostic for mortality
in the critically ill. Also, hypocoagulability as detected
by TEG/ROTEM may aid in diagnosing DIC and hypofi-
brinolysis. Despite heterogeneity and the limited quality of
most included studies, application of TEG/ROTEM seems
a promising tool in sepsis. However, given that coagulopa-
thy is a dynamic process, more insight into the kinetics of
the coagulation alterations, as diagnosed by TEG/ROTEM,
is needed before the general use of TEG/ROTEM to detect
hyper- or hypocoagulability and DIC can be advocated.
Key messages
 Current studies on TEG/ROTEM in patients with
sepsis are of heterogeneous quality, but TEG/
ROTEM could be a promising tool in diagnosing
alterations in coagulation in sepsis.
 Hypocoagulability, as detected by TEG/ROTEM, may
aid in diagnosing disseminated intravascular coagulation.
 An abnormal TEG/ROTEM, in particular, a
hypocoagulable profile, is prognostic for mortality in
the critically ill.
 Further research on the value of TEG/ROTEM in
sepsis is warranted, and sequential measurements
are needed to understand the coagulation patterns,
as can be detected by TEG/ROTEM.
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